Using covariate data to inform the design of large-scale studies

Epidemiology

Volumn 25, Issue 1, 2014, Pages 126-133

  Franklin, Jessica M ^a   Rassen, Jeremy A ^a   Bartels, Dorothee B ^b,c   Schneeweiss, Sebastian ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; STEROID; VALDECOXIB; WARFARIN;

ACUTE HEART INFARCTION; AGED; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; DRUG APPROVAL; DRUG MARKETING; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; METHODOLOGY; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; MULTIVARIATE ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PRODUCT SURVEILLANCE, POSTMARKETING; PROPENSITY SCORE; PROSPECTIVE STUDIES; RESEARCH DESIGN;

EID: 84890125193     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0000000000000020     Document Type: Article

References (21)

1. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel System-A national resource for evidence development. N Engl J Med. 2011;364:498-499
2. C oloma PM, Schuemie MJ, Trifirò G, et al.; EU-ADR Consortium. Combining electronic healthcare databases in Europe to allow for largescale drug safety monitoring: The EU-ADR Project. Pharmacoepidemiol Drug Saf. 2011;20:1-11
3. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323-337
4. Billewicz WZ. The efficiency of matched samples: An empirical investigation. Biometrics. 1965;21:623-644
5. C ochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics. 1968;24:295-313
6. C ochran WG, Rubin DB. Controlling bias in observational studies: A review. Sankhya A. 1973;35:417-446
7. G lynn RJ, Gagne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf. 2012;21(suppl 2):138-147
8. R osenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55
9. R osenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516-524
10. C ole SR, Frangakis CE. The consistency statement in causal inference: A definition or an assumption? Epidemiology. 2009;20:3-5
11. C ole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168:656-664
12. Stürmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: Dealing with observations in the tails of the propensity score distribution-A simulation study. Am J Epidemiol. 2010;172:843-854
13. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: Methodological challenges and implications for drug development. Clin Pharmacol Ther. 2011;90:777-790
14. G agne JJ, Bykov K, Willke RJ, Kahler KH, Subedi P, Schneeweiss S. Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research. Value Health. 2013;16:1054-1062
15. R ay WA. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol. 2003;158:915-920
16. Drake C, McQuarrie A. A note on the bias due to omitted confounders. Biometrika. 1995;82:633-638
17. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-Term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006;17:268-275
18. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: The example of COX2 inhibitors and myocardial infarction. Epidemiology. 2005;16:17-24
19. Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA. Simultaneous assessment of short-Term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: An instrumental variable analysis. Arthritis Rheum. 2006;54:3390-3398
20. C oncato J. When to randomize, or 'Evidence-based medicine needs medicine-based evidence'. Pharmacoepidemiol Drug Saf. 2012;21(suppl 2):6-12
21. Helfand M, Berg A, Flum D, Gabriel S. Draft Methodology Report: Our Questions, Our Decisions: Standards for Patient-centered Outcomes Research. PCORI; 2012. Available at: Http://www.pcori.org/assets/ MethodologyReport- Comment.pdf. Accessed 30 October 2013